Repligen (RGEN) Expected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN) is expected to be issuing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect Repligen to announce earnings of $0.4628 per share and revenue of $206.71 million for the quarter. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the previous year, the company earned $0.26 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, analysts expect Repligen to post $2.06 EPS for the current fiscal year and $2.59 EPS for the next fiscal year.

Repligen Trading Up 0.6%

NASDAQ:RGEN opened at $176.43 on Tuesday. The firm’s fifty day moving average is $176.12 and its 200-day moving average is $146.17. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen has a 52 week low of $100.99 and a 52 week high of $198.87. The firm has a market cap of $9.96 billion, a P/E ratio of 89.05, a P/E/G ratio of 3.20 and a beta of 1.08.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RGEN. Citigroup raised shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Weiss Ratings raised shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Wells Fargo & Company increased their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. increased their price target on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.71.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.